EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The deubiquitinase CYLD inhibits thrombin-induced p38 MAPK–p65 NF-κB signaling and inflammatory cytokine production to suppress triple-negative breast cancer progression

Julio M Pimentel, Oye Bosompra, JoAnn Trejo

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.113341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Julio M Pimentel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Thrombin, Deubiquitinating Enzyme CYLD, p38 Mitogen-Activated Protein Kinases, Triple Negative Breast Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Tobacco-Related Disease Research Program, Burroughs Wellcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by chronic inflammation with limited therapeutic options. Although thrombin activation of protease-activated receptor-1 (PAR1) promotes ubiquitin-dependent signaling and inflammatory responses in endothelial cells, its contribution to inflammatory effects in TNBC remain poorly understood. Here, we show that loss of the deubiquitinase cylindromatosis (CYLD) markedly increases basal phosphorylation of p38 mitogen-activated protein kinase and p65 nuclear factor kappa B subunit to levels comparable to thrombin stimulation, without further enhancement by thrombin, indicating that CYLD primarily restrains constitutive inflammatory activity. We also show that thrombin-activation of PAR1 promotes p38 signaling through an autophosphorylation-dependent mechanism in TNBC, leading to p65 nuclear factor kappa B subunit phosphorylation and nuclear accumulation independent of canonical inhibitor of κBα degradation. This non-canonical signaling drives expression of pro-inflammatory interleukin (IL) cytokines including IL-6, IL-8, IL-1α, and IL-1β. Functionally, IL-6 and IL-8 contribute to thrombin-induced TNBC proliferation and migration, respectively. Together, these findings define a novel CYLD-regulated PAR1-p38-p65 signaling axis that promotes inflammatory cytokine production and tumor-associated phenotypes such as cell proliferation and migration, identifying multiple druggable nodes for therapeutic targeting in aggressive breast cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinDeubiquitinating Enzyme CYLDp38 Mitogen-Activated Protein KinasesTriple Negative Breast NeoplasmsCytokinesTranscription Factor RelAHumansFemaleSignal TransductionDisease ProgressionReceptor, PAR-1Cell Line, Tumor

Stichwörter der Autor:innen

GPCRIL-6IL-8PAR1inflammationinterleukinprotease-activated receptor-1

Substanzen

ThrombinDeubiquitinating Enzyme CYLDp38 Mitogen-Activated Protein KinasesCytokinesTranscription Factor RelACYLD protein, humanReceptor, PAR-1

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California, USA; Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, California, USA.
  • Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California, USA; Moores Cancer Center, University of California San Diego, La Jolla, California, USA. Electronic address: jo…

Förderung

  • NIGMS NIH HHS
  • Tobacco-Related Disease Research Program
  • Burroughs Wellcome Fund
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Pimentel, J. M., Bosompra, O., & Trejo, J. (2026). The deubiquitinase CYLD inhibits thrombin-induced p38 MAPK–p65 NF-κB signaling and inflammatory cytokine production to suppress triple-negative breast cancer progression. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113341

Vancouver

Pimentel JM, Bosompra O, Trejo J. The deubiquitinase CYLD inhibits thrombin-induced p38 MAPK–p65 NF-κB signaling and inflammatory cytokine production to suppress triple-negative breast cancer progression. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113341

BibTeX
@article{Pimentel2026,
  author = {Pimentel, Julio M and Bosompra, Oye and Trejo, JoAnn},
  title = {The deubiquitinase CYLD inhibits thrombin-induced p38 MAPK–p65 NF-κB signaling and inflammatory cytokine production to suppress triple-negative breast cancer progression},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.113341}
}
Kostenlos starten →